Mayo Clinic Graduate School of Biomedical Sciences, Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01275-20.
is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant isolates. Compared to no treatment, treatment resulted in a ≥2-fold log reduction of intracellular rifampin-susceptible, but not rifampin-resistant, These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated .
是假体周围关节感染（PJI）的主要原因；如果治疗药物对细胞内无效，其在成骨细胞内的持续存在可能会影响治疗效果。本研究评估了利福平、利福喷丁和利福布汀对 5 株利福平敏感和 2 株利福平耐药分离株的细胞内活性。与未治疗相比，治疗导致细胞内利福平敏感但不敏感的利福平耐药的对数减少≥2 倍。这些发现表明利福平、利福喷丁和利福布汀对骨内 PJI 相关的具有活性。
